Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087607
Status:
COMPLETED
Last Update Posted:
2016-07-01
First Post:
2004-07-12
Brief Title:
Peak Study - A Study of Pegasys Peginterferon Alfa-2a 40KD in Combination With Copegus Ribavirin in Interferon-Naive Patients With Chronic Hepatitis C CHC
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Prospective Randomized Open-label Study Evaluating the Viral Kinetics and Pharmacokinetics of Pegasys Plus Copegus and PEG-Intron Plus Rebetol in Interferon-naïve Patients With Chronic Hepatitis C
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None